NEW ZEALAND
“De Novo” aHUS is bad luck
It has been known for decades that what is called " de novo " aHUS can happen to a kidney donor…
Funds raised by aHUS people contribute to diagnosis research
Fund raising, which began when aHUSUK still existed, has been put to use to help fund research which may improve the…
The ethics of aHUS treatment trials
When someone is affected by aHUS, the issue of it being a rare disease soon becomes apparent. The injustices felt by…
TMAs and aHUS illustrated
Here is a most unusual clinical article from earlier this year. In Thrombotic microangiopathies : An Illustrated review the Abou-Ismail Group…
Future effects of aHUS and its treatment
A number of questions in the RDD2022 video are about what will happen to patients in the future due to the…
aHUS care pathway
The care pathway for aHUS patients has been looked at in detail in Global Action’s Diagnosis Process Study ( for reports…
Side effects of ravulizimab between infusions
Ravulizumab is more widely used these days, particularly in the PNH community. Apart from the longer infusion intervals PNH patients benefit…
Monitoring after Eculizumab withdrawal
This article marks the 500th website news “blog” since it went live nearly six years ago. That milestone is marked by…
When to transition from eculizumab to ravulizumab
Ravulizumab is eculizumab, Carsten. They work the same way. It is the same monoclonal antibody. It has just been modified in…